Fifth, in the future, we hope to contribute to the treatment of patients suffering from neurological diseases by working on the development of drugs or substances that activate SMAD1 and SMAD4, which are related to nerve regeneration, and drugs or substances that inhibit SMAD2 and SMAD6, which are related to neurodegeneration. This evidence concerns the gene SMAD6 and nervous system disorder.